{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T14:52:59Z","timestamp":1784559179001,"version":"3.55.0"},"reference-count":47,"publisher":"National Institute for Health and Care Research","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment programme","doi-asserted-by":"publisher","award":["16\/31\/136"],"award-info":[{"award-number":["16\/31\/136"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journalslibrary.nihr.ac.uk"],"crossmark-restriction":false},"short-container-title":["Health Technol Assess"],"abstract":"\n Background<\/jats:title>\n In patients with a glioma, 50\u201380% will have seizures during their lifetime and half of these will be drug resistant. Seizure risk is increased perioperatively (around the time of surgery) at tumour progression and shortly before death. In seizure-naive patients with glioma undergoing surgery, existing guidelines do not recommend routine use of prophylactic antiseizure medication. Despite this, an antiseizure medication, levetiracetam, is frequently prescribed perioperatively in many neurosurgical units.<\/jats:p>\n <\/jats:sec>\n \n Objectives<\/jats:title>\n To determine whether in seizure-naive, newly diagnosed cerebral glioma patients undergoing surgery, prophylactic levetiracetam, pre-operatively and for at least 1 year post operatively, produces a meaningful (>\u200550%) reduction in the risk of developing seizures when compared with standard care (no prophylaxis) and is cost-effective.<\/jats:p>\n <\/jats:sec>\n \n Design and methods<\/jats:title>\n We undertook a two-arm, multicentre phase III randomised trial in 14 neurosurgery units across England and Scotland, with an embedded health economic evaluation, comparing 12 months of prophylactic antiseizure medication (levetiracetam) versus no antiseizure medication (comparator) in patients with suspected cerebral glioma undergoing surgery. The target samples size was 804 participants.<\/jats:p>\n <\/jats:sec>\n \n Outcome measures<\/jats:title>\n The primary outcome was the occurrence of a seizure within 12 months of randomisation. The secondary outcomes were time to first seizure, time to first tonic\u2013clonic seizure, time to death (overall survival) and time to tumour recurrence (progression-free survival). The impact of prophylactic levetiracetam on mood, personality, fatigue and memory, severity of first seizure if it occurred and quality of life were assessed. The planned health economic outcomes were costs to the National Health Service and Personal Social Services and incremental cost per quality-adjusted life-year at 12 months and modelled over estimated survival. Analyses were carried out using the intention-to-treat principle.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Between 9 October 2019 and 30 August 2022, 94 patients were recruited, from 24 to 79 years of age and randomised to prophylactic levetiracetam (\n n<\/jats:italic>\n \u2005=\u200549) or no prophylaxis (\n n<\/jats:italic>\n \u2005=\u200545). Due to slow accrual, the trial closed early. Thirteen patients in the prophylactic levetiracetam arm and 9 in the no prophylaxis group died within 1 year of randomisation and did not have a seizure. Of the patients who survived for at least 1 year, 17 (47%) of 36 prophylactic levetiracetam patients had a seizure when compared with 15 (41%) of 36 no prophylaxis patients (odds ratio 1.25, 95% confidence interval 0.49 to 3.21,\n p<\/jats:italic>\n \u2005=\u20050.64). Median time to first seizure was 5.0 months in the prophylactic levetiracetam group and 2.5 months in the no prophylaxis group. In the prophylactic levetiracetam group, 20 (41%) of 49 patients died within 12 months (median overall survival 6.8 months; range 0.2\u201311.9), and in the no prophylaxis group, 14 (31%) of 45 patients died within 12 months (median 4.6 months; range 0.1\u201312.0). At the 3-month and 6-month data collection points, the mean healthcare costs were lower in the prophylactic levetiracetam group (\u00a31175 and \u00a31278) compared with the no prophylaxis group (\u00a32703 and \u00a32767). At the 9-and 12-month data collection points, the mean healthcare costs were higher in the prophylactic levetiracetam group (\u00a31916 and \u00a31238) as compared with the no prophylaxis group (\u00a31597 and \u00a3686). Health-related quality of life as measured by the EuroQol-5 Dimensions, five-level version was similar in the two intervention arms across all time points.\n <\/jats:p>\n <\/jats:sec>\n \n Limitations<\/jats:title>\n The trial was underpowered and closed early due to slow recruitment impacted by the COVID-19 pandemic. Approximately one quarter of patients died within 12 months and did not reach the primary outcome of 1-year risk of seizure.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n Given the trial was underpowered, there was no evidence of a difference in the 12-month seizure risk between the randomised groups and limited evidence regarding potential cost-effectiveness. The role of prophylactic antiseizure medication in glioma surgery remains undefined.<\/jats:p>\n <\/jats:sec>\n \n Future work<\/jats:title>\n SPRING provides the highest quality data available for a future, individual patient data meta-analysis. A definite trial is still needed to answer this clinical question.<\/jats:p>\n <\/jats:sec>\n \n Funding<\/jats:title>\n This synopsis presents independent research funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme as award number 16\/31\/136.<\/jats:p>\n <\/jats:sec>","DOI":"10.3310\/gjmj1815","type":"journal-article","created":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T12:33:13Z","timestamp":1755261193000},"page":"1-40","update-policy":"https:\/\/doi.org\/10.3310\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Seizure prophylaxis in glioma surgery: a synopsis from the SPRING RCT"],"prefix":"10.3310","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4587-2139","authenticated-orcid":true,"given":"Michael D","family":"Jenkinson","sequence":"first","affiliation":[{"name":"The Walton Centre NHS Foundation Trust and University of Liverpool, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6775-5251","authenticated-orcid":true,"given":"Helen","family":"Bulbeck","sequence":"additional","affiliation":[{"name":"Brainstrust \u2013 The Brain Cancer People, Cowes, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jade","family":"Carruthers","sequence":"additional","affiliation":[{"name":"Scottish Clinical Trials Research Unit, Public Health Scotland, Edinburgh, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Burns","sequence":"additional","affiliation":[{"name":"Scottish Clinical Trials Research Unit, Public Health Scotland, Edinburgh, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Lessels","sequence":"additional","affiliation":[{"name":"Scottish Clinical Trials Research Unit, Public Health Scotland, Edinburgh, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Dobbie","sequence":"additional","affiliation":[{"name":"Scottish Clinical Trials Research Unit, Public Health Scotland, Edinburgh, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7366-5890","authenticated-orcid":true,"given":"Rachael","family":"Watson","sequence":"additional","affiliation":[{"name":"Scottish Clinical Trials Research Unit, Public Health Scotland, Edinburgh, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7847-220X","authenticated-orcid":true,"given":"Ciara","family":"Gribben","sequence":"additional","affiliation":[{"name":"Scottish Clinical Trials Research Unit, Public Health Scotland, Edinburgh, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6755-4866","authenticated-orcid":true,"given":"Alasdair G","family":"Rooney","sequence":"additional","affiliation":[{"name":"Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1722-2235","authenticated-orcid":true,"given":"Gerard","family":"Thompson","sequence":"additional","affiliation":[{"name":"Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8695-9738","authenticated-orcid":true,"given":"Tomos","family":"Robinson","sequence":"additional","affiliation":[{"name":"Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8574-8429","authenticated-orcid":true,"given":"Luke","family":"Vale","sequence":"additional","affiliation":[{"name":"Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3411-2505","authenticated-orcid":true,"given":"Sara","family":"Erridge","sequence":"additional","affiliation":[{"name":"Edinburgh Cancer Centre, Crewe Road South, Edinburgh, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3531-8791","authenticated-orcid":true,"given":"Colin","family":"Watts","sequence":"additional","affiliation":[{"name":"Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6861-8806","authenticated-orcid":true,"given":"Anthony G","family":"Marson","sequence":"additional","affiliation":[{"name":"The Walton Centre NHS Foundation Trust and University of Liverpool, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2597-9510","authenticated-orcid":true,"given":"Robin","family":"Grant","sequence":"additional","affiliation":[{"name":"Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6221","published-online":{"date-parts":[[2026,3]]},"reference":[{"key":"key2026030913200000_ref1-bib1","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s12955-025-02348-0","article-title":"A standard gamble study to determine health state utilities associated with seizures in glioma in the UK","volume":"23","author":"Robinson","year":"2025","journal-title":"Health Qual Life Outcomes"},{"key":"key2026030913200000_ref2-bib2","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1023\/A:1005861024679","article-title":"Incidence studies of primary and secondary intracranial tumors: a systematic review of their methodology and results","volume":"37","author":"Counsell","year":"1998","journal-title":"J Neurooncol"},{"key":"key2026030913200000_ref3-bib3","first-page":"27","article-title":"Epilepsy in patients with brain tumors and other cancers","volume":"1","author":"Bromfield","year":"2004","journal-title":"Rev Neurol Dis"},{"key":"key2026030913200000_ref4-bib4","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S1474-4422(07)70103-5","article-title":"Epilepsy in patients with brain tumours: epidemiology, mechanisms, and management","volume":"6","author":"van Breemen","year":"2007","journal-title":"Lancet Neurol"},{"key":"key2026030913200000_ref5-bib5","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1097\/WCO.0b013e32833e996c","article-title":"Epilepsy in brain tumor patients","volume":"23","author":"Rossetti","year":"2010","journal-title":"Curr Opin Neurol"},{"key":"key2026030913200000_ref6-bib6","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.3171\/2016.4.JNS16245","article-title":"Prophylactic antiepileptic drug administration following brain tumor resection: results of a recent AANS\/CNS Section on Tumors survey","volume":"126","author":"Dewan","year":"2017","journal-title":"J Neurosurg"},{"key":"key2026030913200000_ref7-bib7","doi-asserted-by":"crossref","first-page":"359","DOI":"10.3171\/jns.1980.52.3.0359","article-title":"The effect of phenobarbital on the toxicity and tumoricidal activity of CCNU in a murine brain tumor model","volume":"52","author":"Muller","year":"1980","journal-title":"J Neurosurg"},{"key":"key2026030913200000_ref8-bib8","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1212\/WNL.46.4.985","article-title":"A randomized, blinded, placebo-controlled trial of divalproex sodium prophylaxis in adults with newly diagnosed brain tumors","volume":"46","author":"Glantz","year":"1996","journal-title":"Neurology"},{"key":"key2026030913200000_ref9-bib9","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1016\/j.clineuro.2013.08.023","article-title":"Considerations in prophylaxis for tumor-associated epilepsy: prevention of status epilepticus and tolerability of newer generation AEDs","volume":"115","author":"Wychowski","year":"2013","journal-title":"Clin Neurol Neurosurg"},{"key":"key2026030913200000_ref10-bib10","first-page":"847","article-title":"The end-of-life phase of high-grade glioma patients: a systematic review","volume":"22","author":"Sizoo","year":"2014","journal-title":"Support Care Cancer"},{"key":"key2026030913200000_ref11-bib11","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s11060-012-0993-2","article-title":"Epilepsy in the end-of-life phase in patients with high-grade gliomas","volume":"111","author":"Pace","year":"2013","journal-title":"J Neurooncol"},{"key":"key2026030913200000_ref12-bib12","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1136\/bmjspcare-2013-000456","article-title":"Seizures in patients with high-grade glioma: a serious challenge in the end-of-life phase","volume":"4","author":"Sizoo","year":"2014","journal-title":"BMJ Support Palliat Care"},{"key":"key2026030913200000_ref13-bib13","first-page":"134","article-title":"Epilepsy in the end of life phase of brain tumor patients: a systematic review","volume":"1","author":"Koekkoek","year":"2014","journal-title":"Neurooncol Pract"},{"key":"key2026030913200000_ref14-bib14","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1093\/neuonc\/noab152","article-title":"SNO and EANO practice guideline update: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors","volume":"23","author":"Walbert","year":"2021","journal-title":"Neuro Oncol"},{"key":"key2026030913200000_ref15-bib15","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1093\/neuonc\/noad154","article-title":"Brain tumor-related epilepsy management: a Society for Neuro-oncology (SNO) consensus review on current management","volume":"26","author":"Avila","year":"2024","journal-title":"Neuro Oncol"},{"key":"key2026030913200000_ref16-bib16","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1227\/00006123-198503000-00002","article-title":"Postoperative prophylactic anticonvulsant therapy in cerebral gliomas","volume":"16","author":"Boarini","year":"1985","journal-title":"Neurosurgery"},{"key":"key2026030913200000_ref17-bib17","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1001\/archneur.1995.00540310091021","article-title":"The course of seizure disorders in patients with malignant gliomas","volume":"52","author":"Moots","year":"1995","journal-title":"Arch Neurol"},{"key":"key2026030913200000_ref18-bib18","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1017\/S0317167100053361","article-title":"Prophylactic anticonvulsants in patients with brain tumour","volume":"30","author":"Forsyth","year":"2003","journal-title":"Can J Neurol Sci"},{"key":"key2026030913200000_ref19-bib19","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/BF01420191","article-title":"Influence of surgery and antiepileptic drugs on seizures symptomatic of cerebral tumours","volume":"103","author":"Franceschetti","year":"1990","journal-title":"Acta Neurochir (Wien)"},{"key":"key2026030913200000_ref20-bib20","doi-asserted-by":"crossref","first-page":"672","DOI":"10.3171\/jns.1983.58.5.0672","article-title":"Phenytoin and postoperative epilepsy: a double-blind study","volume":"58","author":"North","year":"1983","journal-title":"J Neurosurg"},{"key":"key2026030913200000_ref21-bib21","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s11060-008-9781-4","article-title":"Safety and feasibility of switching from phenytoin to levetiracetam monotherapy for glioma-related seizure control following craniotomy: a randomized phase II pilot study","volume":"93","author":"Lim","year":"2009","journal-title":"J Neurooncol"},{"key":"key2026030913200000_ref22-bib22","doi-asserted-by":"crossref","first-page":"67.e4","DOI":"10.1136\/jnnp-2015-312379.159","article-title":"Levetiracetam is independently associated with fatigue in adult glioma outpatients","volume":"86","author":"Zienius","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"key2026030913200000_ref23-bib23","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1001\/archneurol.2012.445","article-title":"Results of phase 2 safety and feasibility study of treatment with levetiracetam for prevention of posttraumatic epilepsy","volume":"69","author":"Klein","year":"2012","journal-title":"Arch Neurol"},{"key":"key2026030913200000_ref24-bib24","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1093\/neuonc\/nos288","article-title":"Levetiracetam improves verbal memory in high-grade glioma patients","volume":"15","author":"de Groot","year":"2013","journal-title":"Neuro-Oncol"},{"key":"key2026030913200000_ref25-bib25","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1093\/neuonc\/noq044","article-title":"Levetiracetam enhances p53-mediated MGMT inhibition and sensitizes glioblastoma cells to temozolomide","volume":"12","author":"Bobustuc","year":"2010","journal-title":"Neuro-Oncol"},{"key":"key2026030913200000_ref26-bib26","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1093\/neuonc\/nov269","article-title":"Epilepsy in glioma patients: mechanisms, management, and impact of anticonvulsant therapy","volume":"18","author":"Armstrong","year":"2016","journal-title":"Neuro Oncol"},{"key":"key2026030913200000_ref27-bib27","first-page":"123","article-title":"Time to focus on brain tumor-related epilepsy trials","volume":"1","author":"Gallagher","year":"2014","journal-title":"Neurooncol Pract"},{"key":"key2026030913200000_ref28-bib28","volume-title":"Evaluation of Chemotherapeutic Agents","author":"Karnofsky","year":"1949"},{"key":"key2026030913200000_ref29-bib29","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1111\/j.1528-1157.2000.tb00317.x","article-title":"Patient-based assessments of quality of life in newly diagnosed epilepsy patients: validation of the NEWQOL","volume":"41","author":"Abetz","year":"2000","journal-title":"Epilepsia"},{"key":"key2026030913200000_ref30-bib30","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1046\/j.1525-1497.2001.016009606.x","article-title":"The PHQ-9: validity of a brief depression severity measure","volume":"16","author":"Kroenke","year":"2001","journal-title":"J Gen Intern Med"},{"key":"key2026030913200000_ref31-bib31","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.yebeh.2012.11.046","article-title":"The reliability and validity of the Revised Liverpool Impact of Epilepsy Scale for use in people with new-onset epilepsy","volume":"26","author":"Crossley","year":"2013","journal-title":"Epilepsy Behav"},{"key":"key2026030913200000_ref32-bib32","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S1059-1311(98)80036-8","article-title":"Liverpool Seizure Severity Scale revisited","volume":"7","author":"Baker","year":"1998","journal-title":"Seizure"},{"key":"key2026030913200000_ref34-bib34","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s12883-022-02655-9","article-title":"Verbal fluency as a quick and simple tool to help in deciding when to refer patients with a possible brain tumour","volume":"22","author":"Zienius","year":"2022","journal-title":"BMC Neurol"},{"key":"key2026030913200000_ref35-bib35","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","article-title":"Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)","volume":"20","author":"Herdman","year":"2011","journal-title":"Qual Life Res"},{"key":"key2026030913200000_ref36-bib36","unstructured":"Hernandez Alava M, Pudney S, Wailoo A. Estimating EQ-5D by Age and Sex for the UK. NICE DSU Report. 2022."},{"key":"key2026030913200000_ref37-bib37","volume-title":"British National Formulary","author":"Joint Formulary Committee","year":"2024"},{"key":"key2026030913200000_ref38-bib38","doi-asserted-by":"crossref","DOI":"10.1093\/nop\/npaf114","article-title":"Seizure prophylaxis in glioma surgery (SPRING): A multi-center, unblinded, randomized trial [published online ahead of print November 5 2025]","author":"Jenkinson","year":"2025","journal-title":"Neuro Oncol Pract"},{"key":"key2026030913200000_ref39-bib39","doi-asserted-by":"crossref","first-page":"985","DOI":"10.3171\/2019.1.JNS19134","article-title":"Letter to the Editor. Establishing the role of prophylactic antiepileptic drugs in glioma and meningioma surgery","volume":"131","author":"Jenkinson","year":"2019","journal-title":"J Neurosurg"},{"key":"key2026030913200000_ref40-bib40","doi-asserted-by":"crossref","first-page":"10783","DOI":"10.1038\/s41598-020-67697-w","article-title":"Association between survival and levetiracetam use in glioblastoma patients treated with temozolomide chemoradiotherapy","volume":"10","author":"Roh","year":"2020","journal-title":"Sci Rep"},{"key":"key2026030913200000_ref41-bib41","first-page":"e125","article-title":"Effect of levetiracetam use duration on overall survival of isocitrate dehydrogenase wild-type glioblastoma in adults: an observational study","volume":"98","author":"Pallud","year":"2022","journal-title":"Neurology"},{"key":"key2026030913200000_ref42-bib42","doi-asserted-by":"crossref","first-page":"3770","DOI":"10.3390\/cancers13153770","article-title":"How about levetiracetam in glioblastoma? An institutional experience and meta-analysis","volume":"13","author":"Jabbarli","year":"2021","journal-title":"Cancers"},{"key":"key2026030913200000_ref43-bib43","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1212\/WNL.54.10.1886","article-title":"Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors: report of the Quality Standards Subcommittee of the American Academy of Neurology","volume":"54","author":"Glantz","year":"2000","journal-title":"Neurology"},{"key":"key2026030913200000_ref44-bib44","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/S0140-6736(07)60461-9","article-title":"The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial","volume":"369","author":"Marson","year":"2007","journal-title":"Lancet"},{"key":"key2026030913200000_ref45-bib45","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/S0140-6736(07)60460-7","article-title":"The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial","volume":"369","author":"Marson","year":"2007","journal-title":"Lancet"},{"key":"key2026030913200000_ref46-bib46","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/S0140-6736(21)00246-4","article-title":"The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial","volume":"397","author":"Marson","year":"2021","journal-title":"Lancet"},{"key":"key2026030913200000_ref47-bib47","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s11060-018-2862-0","article-title":"Tumor-related epilepsy: epidemiology, pathogenesis and management","volume":"139","author":"Chen","year":"2018","journal-title":"J Neurooncol"},{"key":"key2026030913200000_ref48-bib48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s007010050001","article-title":"The pathogenesis of tumour associated epilepsy","volume":"142","author":"Beaumont","year":"2000","journal-title":"Acta Neurochir"}],"container-title":["Health Technology Assessment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2050513","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/sites\/journalslibrary\/files\/journal_data\/GJMJ1815\/GJMJ1815.xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2050513","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T08:00:00Z","timestamp":1773043200000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/hta\/GJMJ1815"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":47,"alternative-id":["10.3310\/GJMJ1815"],"URL":"https:\/\/doi.org\/10.3310\/gjmj1815","relation":{},"ISSN":["2046-4924"],"issn-type":[{"value":"2046-4924","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"This content has been made freely available to all.","name":"free","label":"Free to read"},{"value":"04-2018","name":"contractual_start_date","label":"contractual_start_date","group":{"name":"article_history","label":"Article History"}},{"value":"03-2025","name":"editorial_review_begun","label":"editorial review begun","group":{"name":"article_history","label":"Article History"}},{"value":"09-2025","name":"accepted_for_publication","label":"Accepted for publication","group":{"name":"article_history","label":"Article History"}}]}}